Logo image of OBIO

ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Fundamental Analysis

NASDAQ:OBIO - Nasdaq - US68572M1062 - Common Stock - Currency: USD

3.34  0 (0%)

After market: 3.34 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OBIO. OBIO was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of OBIO have multiple concerns. OBIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OBIO has reported negative net income.
In the past year OBIO has reported a negative cash flow from operations.
OBIO had negative earnings in each of the past 5 years.
In the past 5 years OBIO always reported negative operating cash flow.
OBIO Yearly Net Income VS EBIT VS OCF VS FCFOBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -112.30%, OBIO is not doing good in the industry: 84.57% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -393.40%, OBIO is doing worse than 86.70% of the companies in the same industry.
Industry RankSector Rank
ROA -112.3%
ROE -393.4%
ROIC N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OBIO Yearly ROA, ROE, ROICOBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

OBIO has a better Gross Margin (92.58%) than 100.00% of its industry peers.
OBIO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for OBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
OBIO Yearly Profit, Operating, Gross MarginsOBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 1K -1K 2K -2K

More info and screens

3

2. Health

2.1 Basic Checks

OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OBIO has more shares outstanding
Compared to 1 year ago, OBIO has a worse debt to assets ratio.
OBIO Yearly Shares OutstandingOBIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
OBIO Yearly Total Debt VS Total AssetsOBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -9.03, we must say that OBIO is in the distress zone and has some risk of bankruptcy.
OBIO has a worse Altman-Z score (-9.03) than 79.26% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that OBIO is somewhat dependend on debt financing.
OBIO has a Debt to Equity ratio of 0.85. This is in the lower half of the industry: OBIO underperforms 75.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Altman-Z -9.03
ROIC/WACCN/A
WACC8.86%
OBIO Yearly LT Debt VS Equity VS FCFOBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 3.35 indicates that OBIO has no problem at all paying its short term obligations.
OBIO has a Current ratio (3.35) which is in line with its industry peers.
A Quick Ratio of 3.34 indicates that OBIO has no problem at all paying its short term obligations.
OBIO's Quick ratio of 3.34 is fine compared to the rest of the industry. OBIO outperforms 66.49% of its industry peers.
Industry RankSector Rank
Current Ratio 3.35
Quick Ratio 3.34
OBIO Yearly Current Assets VS Current LiabilitesOBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

OBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.59%.
The Revenue has grown by 29.88% in the past year. This is a very strong growth!
EPS 1Y (TTM)-19.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.95%
Revenue 1Y (TTM)29.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40%

3.2 Future

OBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.10% yearly.
OBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 76.15% yearly.
EPS Next Y-22.99%
EPS Next 2Y-5.07%
EPS Next 3Y0.05%
EPS Next 5Y11.1%
Revenue Next Year1.24%
Revenue Next 2Y-2.96%
Revenue Next 3Y2.21%
Revenue Next 5Y76.15%

3.3 Evolution

OBIO Yearly Revenue VS EstimatesOBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50M 100M 150M
OBIO Yearly EPS VS EstimatesOBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBIO Price Earnings VS Forward Price EarningsOBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OBIO Per share dataOBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.07%
EPS Next 3Y0.05%

More info and screens

0

5. Dividend

5.1 Amount

OBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (6/10/2025, 6:29:04 PM)

After market: 3.34 0 (0%)

3.34

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)N/A N/A
Inst Owners43.2%
Inst Owner Change-1.17%
Ins Owners4.1%
Ins Owner Change3.82%
Market Cap127.96M
Analysts84.62
Price Target13.84 (314.37%)
Short Float %4.71%
Short Ratio2.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.13%
Max EPS beat(2)3.57%
EPS beat(4)3
Avg EPS beat(4)-0.53%
Min EPS beat(4)-12.33%
Max EPS beat(4)6.52%
EPS beat(8)7
Avg EPS beat(8)3.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-11.36%
Min Revenue beat(2)-70.51%
Max Revenue beat(2)47.79%
Revenue beat(4)2
Avg Revenue beat(4)0.66%
Min Revenue beat(4)-70.51%
Max Revenue beat(4)47.79%
Revenue beat(8)3
Avg Revenue beat(8)-16.71%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.65%
PT rev (3m)-8.3%
EPS NQ rev (1m)-5.31%
EPS NQ rev (3m)-4.01%
EPS NY rev (1m)-0.71%
EPS NY rev (3m)-4.24%
Revenue NQ rev (1m)-11.4%
Revenue NQ rev (3m)-10.6%
Revenue NY rev (1m)7.74%
Revenue NY rev (3m)-13.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 44.34
P/FCF N/A
P/OCF N/A
P/B 7.59
P/tB 7.59
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS0.08
BVpS0.44
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -112.3%
ROE -393.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.58%
FCFM N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 313.88%
Cap/Sales 34.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.35
Quick Ratio 3.34
Altman-Z -9.03
F-Score3
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)194.88%
Cap/Depr(5y)224.07%
Cap/Sales(3y)17.77%
Cap/Sales(5y)19.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.95%
EPS Next Y-22.99%
EPS Next 2Y-5.07%
EPS Next 3Y0.05%
EPS Next 5Y11.1%
Revenue 1Y (TTM)29.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40%
Revenue Next Year1.24%
Revenue Next 2Y-2.96%
Revenue Next 3Y2.21%
Revenue Next 5Y76.15%
EBIT growth 1Y-26.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.05%
EBIT Next 3Y-12%
EBIT Next 5Y2.91%
FCF growth 1Y-41.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.96%
OCF growth 3YN/A
OCF growth 5YN/A